A medicinal fungus composition for treating hyperlipidemia, and its preparation method and application
By adding tea powder and intestinal probiotic Akkermansia muciniphila to vinegar paste for fermentation, combined with distillation and concentration and ultrafine crushing technology, the prepared drug bacteria composition solves the problems of drug side effects and limited effects in the treatment of hyperlipidemia, achieving the goal of achieving It significantly reduces blood lipid levels and has safe therapeutic effects.
Patent Information
- Application Number
- CN202311030575.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-08-16
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-08-16
AI Technical Summary
The existing treatment methods for hyperlipidemia have problems such as major side effects of drugs, limited therapeutic effects and dietary exercise control that requires long-term persistence. Traditional drugs have a greater burden on the liver and kidneys and have poor results.
Combining traditional Chinese medicine and probiotics, by adding tea powder and intestinal probiotic Akkermansia muciniphila to vinegar paste for fermentation, a medicinal bacteria composition is prepared, and the ultra-fine crushing method is used to improve the wall breakage rate and efficacy of tea, combined with distillation and concentration Technology improves the function of vinegar paste and adds fruit pulp to improve taste and regulate intestinal bacterial flora.
It significantly reduces blood lipid levels, improves the effect of treating hyperlipidemia, reduces the adverse reactions of drugs to the body, has a short onset time and a small metabolic burden, and is safe and has no toxic side effects.
Smart Images

Figure BDA0004397124970000111 
Figure BDA0004397124970000121
Abstract
Description
Technical Field
[0001] The invention relates to a medicinal fungus composition for treating hyperlipidemia and a preparation method and application thereof, belonging to the field of biotechnology. Background Art
[0002] Hyperlipidemia is a disease that includes various genetic and acquired diseases, which is characterized by elevated lipid levels in the human body. According to statistics, the incidence of dyslipidemia among Chinese adults exceeds 25%, which means that one in every four people is a potential hyperlipidemia patient. According to statistics from the World Health Organization, approximately 17 million people die from this chronic disease each year, accounting for about 30% of the total global death toll. The main factors that affect the body's blood lipid levels are environmental factors, including high cholesterol, high-sugar diets, obesity, and long-term sitting.
[0003] At present, most of the treatments for hyperlipidemia are Western medicine. When the blood lipids in the body reach a certain index, lipid-lowering drugs such as statins, fibrates and niacin can be taken. However, drug treatment has great side effects on the human body, and long-term medication will add a certain burden to the liver and kidney organs. At the same time, if the symptoms are mild, they can be controlled through diet and exercise, but long-term persistence is required to achieve a certain effect. Fungal drugs are considered to be a new trend in drug development due to their low toxicity, safety, and pharmacological activity such as regulating immune function.
[0004] Akkermansia muciniphila is a new mucin-degrading bacterium found in human feces by Derrien in 2004. It belongs to the phylum Verrucomycetes. Akkermansia muciniphila is ubiquitous in the human intestine and feeds on mucin. Low concentrations of Akkermansia muciniphila in the intestine may indicate a thin mucus layer, leading to weakened intestinal barrier function. Akkermansia muciniphila and its secretions bind to Toll receptors of colonic epithelial cells and regulate the expression of tight junction proteins to maintain intestinal homeostasis, thereby improving diseases such as obesity and inflammatory bowel disease induced by a high-fat diet. Existing reports indicate that blood sugar or blood lipid levels can be suppressed by regulating the abundance of beneficial bacteria such as Akkermansia muciniphila in the intestinal microbial flora, but the therapeutic effect is very limited. Summary of the invention
[0005] To solve the above problems, the present invention combines traditional Chinese medicine and probiotics, adds tea powder and intestinal probiotics Akkermansia muciniphila to vinegar paste for fermentation, which can be used as a drug for treating hyperlipidemia, has a smaller metabolic burden on the human body and a shorter onset time than diet and exercise control, overcomes the adverse reactions that traditional drug treatment may cause to the body, and also has important social prospects and economic benefits.
[0006] The first object of the present invention is to provide a method for preparing a medicinal fungus composition for treating hyperlipidemia, comprising the following steps:
[0007] S1, preparing vinegar paste by distillation and concentration method, mixing with tea powder to obtain tea vinegar mixture;
[0008] S2, anaerobically fermenting Akkermansia muciniphila at 35-38° C. for 35-45 hours to obtain live bacteria;
[0009] S3, adding the tea vinegar mixture to the live bacteria culture medium, and anaerobically fermenting at 35-38° C. for 15-35 hours to obtain a medicinal bacteria mixture;
[0010] S4. The above-mentioned medicinal fungus mixture is prepared and sterilized to obtain the medicinal fungus composition for treating hyperlipidemia.
[0011] Hyperlipidemia is related to excessive intake of foods containing fat and cholesterol, as well as genetic factors. The damage caused by hyperlipidemia to the body is hidden, gradual, progressive and systemic. Its direct damage is to accelerate systemic atherosclerosis, because all important organs in the body rely on arteries for blood and oxygen supply. Once the arteries are blocked by atherosclerotic plaques, serious consequences will occur.
[0012] The green tea leaves of the present invention are rich in alkaloids, fats, free amino acids, organic acids, proteins, carbohydrates and tea polyphenols, among which tea polyphenols account for a large proportion, and tea polyphenols are composed of catechins, flavonoids, anthocyanins and other substances, and flavonoids play an important role in anti-oxidation, lipase inhibition, anti-cancer, antibacterial and anti-inflammatory aspects.
[0013] The invention utilizes the ultrafine grinding method to grind the green tea leaves, has a high wall-breaking rate for the green tea leaves, and the obtained tea leaves particles are fine and have better rehydration properties, are beneficial to the release and absorption of the drug, and the drug efficacy is significantly enhanced.
[0014] The vinegar paste in the present invention is a traditional Chinese medicinal material that is both medicinal and edible. It is rich in active substances such as organic acids, polysaccharides, proteins, flavonoids, polyphenols, and ligustrazine. It can effectively reduce cholesterol, triglycerides, and low-density lipoprotein cholesterol in the body through dietary intervention, increase high-density lipoprotein cholesterol in the body, and reduce the content of malondialdehyde in the liver, which has a certain effect of lowering blood lipids; and polyphenols and flavonoids have antioxidant effects, which can inhibit lipid peroxidation and lipase activity. Not only that, the vinegar paste can also affect the health of the intestine and the body by increasing the potential beneficial bacteria Akkermansia in the intestine.
[0015] In addition, the present invention utilizes distillation and concentration technology to prepare the vinegar paste, thereby increasing the aging rate of the vinegar paste, accelerating the enrichment of active ingredients, and improving the function and quality of the vinegar paste.
[0016] The tea vinegar mixture of the present invention is combined with live Akkermansia muciniphila bacteria. Akkermansia muciniphila and its secretions bind to the Toll receptors of colon epithelial cells and regulate the expression of tight junction proteins to maintain intestinal homeostasis, thereby improving diseases such as obesity and inflammatory bowel disease induced by a high-fat diet. In addition, the tea vinegar mixture combined with Akkermansia muciniphila bacteria can regulate intestinal flora, enhance intestinal barrier function, further reduce the production of LPS, and play a certain role in treating hyperlipidemia.
[0017] Furthermore, in step S1, the preparation method of the vinegar paste is to heat the vinegar at 60°C to 80°C for 20 to 30 hours for distillation and concentration, collect the concentrated vinegar liquid, add the yeast extract thereto, mix well and separate the layers, and take the lower layer liquid to obtain the vinegar paste.
[0018] Furthermore, the mass ratio of concentrated vinegar liquid to yeast extract is 100-300:1-1.5.
[0019] Furthermore, the tea powder is obtained by crushing green tea leaves by ultrafine grinding method. Specifically, high-quality green tea leaves are crushed by ultrafine grinding method, the speed of the ultrafine grinder is 340-360r / min, the ball-to-material ratio is 7-9, and the crushing time is 3-4h to obtain tea powder.
[0020] Furthermore, in the tea-vinegar mixture, the vinegar paste accounts for 20 to 30% of the mass of the tea powder.
[0021] Furthermore, step S1 also includes the steps of filtering, removing impurities, homogenizing and sterilizing the vinegar paste.
[0022] Furthermore, homogenization includes but is not limited to high-pressure homogenization to make the vinegar paste particles uniform, such as processing with a homogenizer at 20° C. to 30° C. and a pressure of 15 to 25 MPa.
[0023] Furthermore, sterilization includes but is not limited to high temperature sterilization, such as sterilization at 130-170°C.
[0024] Further, in step S2 or S3, Akkermansia muciniphila is cultured using a food-grade culture medium according to the HACCP quality system.
[0025] Furthermore, the Akkermansia muciniphila is Akkermansiamuciniphila ATCC BAA-835, purchased from the American Type Culture Collection (ATCC).
[0026] Furthermore, in step S3, the amount of Akkermansia muciniphila added is 4×10 8 ~4×10 11 pcs / 100mL tea vinegar mixture.
[0027] Furthermore, in step S4, the preparation is to add fruit pulp to the medicinal fungus mixture. The fruit pulp in the present invention is a mixed pulp of pitaya, kiwi fruit and cherry tomatoes. Pitaya contains prebiotics, which can feed healthy bacteria in the intestines called probiotics; and pitaya can lower blood sugar and promote digestion and absorption. This pulp is rich in pectin, flavonoids, polyphenols, vitamins, etc., which has the functions of enhancing and regulating human immunity, anti-oxidation, anti-inflammatory, etc. At the same time, fruit pulp can also improve the taste of the medicinal fungus composition.
[0028] Furthermore, the amount of fruit pulp added is 10% to 20% of the mass of the prepared medicinal fungus mixture.
[0029] Furthermore, the fruit pulp is clarified fruit pulp obtained by pulping and enzymolysis of fruit pulp.
[0030] Furthermore, the enzymatic hydrolysis process is to add cellulase and pectinase to the pulped pulp for enzymatic hydrolysis, the enzymatic hydrolysis temperature is 45-55° C., and the enzymatic hydrolysis time is 2-3 hours.
[0031] Furthermore, 0.1% to 0.2% of cellulase and 0.2% to 0.3% of pectinase are added to the total weight of the pulp for enzymolysis.
[0032] Furthermore, the fruits are selected from at least two of apples, pitaya, cherry tomatoes and kiwifruit. Preferably, the pulp raw material is pitaya, kiwifruit and cherry tomatoes mixed in a mass ratio of 7-8:6-7:4-5.
[0033] Furthermore, in step S4, the prepared drug-bacteria mixture is sterilized by high pressure homogenization at 140-160 MPa and 40-50°C.
[0034] The second object of the present invention is to provide a medicinal fungus composition obtained by the above preparation method.
[0035] The third object of the present invention is to provide the use of the above-mentioned medicinal fungus composition in the preparation of drugs for preventing or treating hyperlipidemia.
[0036] Beneficial effects of the present invention:
[0037] (1) Based on the analysis of clinical test data, the present invention provides a new use of the medicinal fungus composition in the treatment of hyperlipidemia through a large number of animal experimental screenings and in-depth research. The experimental results show that the medicinal fungus composition can significantly reduce blood lipid levels after being gavaged into rats, and has a therapeutic effect on hyperlipidemia model rats. In addition, the experimental results show that the medicinal fungus composition of the present invention has reliable efficacy, is safe to use, has no toxic side effects, and can be used to prepare food or medicine for the treatment of hyperlipidemia.
[0038] (2) The present invention adds intestinal probiotics Akkermansia muciniphila to the tea-vinegar mixture for fermentation. Compared with the traditional compound medicinal fungus composition, the utilization rate of medicinal materials is effectively improved, and the adverse reactions caused by traditional drug treatment to the body are overcome. It has been verified that the medicinal fungus composition obtained by fermentation of the probiotics of the present invention also improves the therapeutic effect of hyperlipidemia. DETAILED DESCRIPTION
[0039] The present invention is further described below in conjunction with specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0040] The materials and methods involved in the following examples are as follows:
[0041] Yeast extract: Angel Yeast.
[0042] Akkermansia muciniphila: Cat. No. BAA-835, purchased from American Type Culture Collection (ATCC).
[0043] Akkermansia muciniphila culture medium: Standard brain heart infusion (BHI) medium with the following components added: mucin (0.25%), L-cysteine (0.1 mL of 3% stock solution per 10 mL of culture medium).
[0044] Example 1: Preparation method of a medicinal fungus composition for treating hyperlipidemia
[0045] (1) Preparation of tea-vinegar mixture: Use ultrafine grinding method to grind high-quality green tea leaves. During the grinding, the speed of the ultrafine grinder is 340r / min, the ball-to-material ratio is 8, and the grinding time is 3h to obtain tea powder. Heat and concentrate the vinegar at a temperature of 80°C for 20h, and collect the distilled vinegar liquid and concentrated vinegar liquid. Add a certain amount of yeast extract to the concentrated vinegar liquid at a ratio of 1:200, mix well, let stand, and take the lower layer liquid to obtain the prepared vinegar paste. Then add 20% of the vinegar paste by weight of the tea powder and mix to obtain a tea-vinegar mixture;
[0046] (2) Preparation of Akkermansia muciniphila: According to the HACCP quality system, the bacteria were cultured using food-grade culture medium and fermented under anaerobic conditions at 37° C. for 40 h to obtain live Akkermansia muciniphila for later use;
[0047] (3) Pretreatment of fruit raw materials: Wash the fruit raw materials twice or take out the pulp, mix pitaya, kiwi fruit and cherry tomatoes in a mass ratio of 7:6:4 for pulping, add 0.1% of the total mass of the pulp cellulase and 0.2% of pectinase to the pulped pulp, the enzymolysis temperature is 45-55°C, and the enzymolysis time is 2-3h. After grinding with a colloid mill, fresh pulp is obtained for use;
[0048] (4) Preparation of the medicinal fungus mixture: adding the live Akkermansia muciniphila obtained in step (2) to the tea vinegar mixture obtained in step (1), and fermenting under anaerobic conditions at 37° C. for 15 hours to obtain the medicinal fungus mixture;
[0049] The amount of live Akkermansia muciniphila added was 4×10 8 pcs / 100mL tea vinegar mixture
[0050] (5) blending: adding the fruit pulp obtained in step (3) to the medicinal fungus mixture obtained in step (4) for blending;
[0051] The clarified pulp accounts for 10% of the mass of the medicinal fungus mixture.
[0052] (6) High-pressure homogenization sterilization: The medicinal fungus composition is subjected to homogenization sterilization treatment at 150 MPa and 45° C. to finally obtain a medicinal fungus composition for treating hyperlipidemia.
[0053] Example 2: Preparation method of a medicinal fungus composition for treating hyperlipidemia
[0054] (1) Preparation of tea vinegar mixture: Use ultrafine grinding method to grind high-quality green tea leaves. During the grinding, the speed of the ultrafine grinder is 350r / min, the ball-to-material ratio is 7, and the grinding time is 3.5h to obtain tea powder. Heat and concentrate the vinegar at a temperature of 80°C for 20h, and collect the distilled vinegar liquid and concentrated vinegar liquid. Add a certain amount of yeast extract to the concentrated vinegar liquid at a ratio of 1:200, mix well, let stand, and take the lower layer liquid to obtain the prepared vinegar paste. Then add 30% of the mass of the tea powder to the vinegar paste and mix to obtain a tea vinegar mixture.
[0055] (2) Preparation of Akkermansia muciniphila bacteria: According to the HACCP quality system, the bacteria were cultured using food-grade culture medium and fermented under anaerobic conditions at 37° C. for 42 h to obtain live Akkermansia muciniphila bacteria for use;
[0056] (3) Pretreatment of fruit raw materials: Wash the fruit raw materials twice or take out the pulp, mix pitaya, kiwi fruit and cherry tomatoes in a mass ratio of 8:7:4 for pulping, add 0.1% of the total mass of the pulp cellulase and 0.2% of pectinase to the pulped pulp, the enzymolysis temperature is 45-55°C, and the enzymolysis time is 2-3h. After grinding with a colloid mill, fresh pulp is obtained for use;
[0057] (4) Preparation of the medicinal fungus mixture: adding the live Akkermansia muciniphila obtained in step (2) to the tea vinegar mixture obtained in step (1), and fermenting under anaerobic conditions at 37° C. for 20 hours to obtain the medicinal fungus mixture;
[0058] The amount of live Akkermansia muciniphila added was 4×10 8 pcs / 100mL tea vinegar mixture.
[0059] (5) blending: adding the fruit pulp obtained in step (3) to the medicinal fungus mixture obtained in step (4) for blending;
[0060] The amount of fruit pulp added is 15% of the mass of the medicinal fungus mixture.
[0061] (6) High-pressure homogenization sterilization: The medicinal fungus composition is subjected to homogenization sterilization treatment at 150 MPa and 45° C. to finally obtain a medicinal fungus composition for treating hyperlipidemia.
[0062] Example 3: Preparation method of a medicinal fungus composition for treating hyperlipidemia
[0063] (1) Preparation of tea vinegar mixture: Use ultrafine grinding method to grind high-quality green tea leaves. During the grinding, the speed of the ultrafine grinder is 350r / min, the ball-to-material ratio is 8, and the grinding time is 3.5h to obtain tea powder. Heat and concentrate the vinegar at a temperature of 80°C for 20h, and collect the distilled vinegar liquid and concentrated vinegar liquid. Add a certain amount of yeast extract to the concentrated vinegar liquid at a ratio of 1:200, mix well, let stand, and take the lower layer liquid to obtain the prepared vinegar paste. Then add 20% of the vinegar paste of the mass of the tea powder and mix to obtain a tea vinegar mixture.
[0064] (2) Preparation of Akkermansia muciniphila: According to the HACCP quality system, the bacteria were cultured using food-grade culture medium and fermented under anaerobic conditions at 37° C. for 40 h to obtain live Akkermansia muciniphila for later use;
[0065] (3) Pretreatment of fruit raw materials: Wash the fruit raw materials twice or take out the pulp, mix pitaya, kiwi fruit and cherry tomatoes in a mass ratio of 8:7:5 for pulping, add 0.1% of the total mass of the pulp cellulase and 0.2% of pectinase to the pulped pulp, the enzymolysis temperature is 45-55°C, and the enzymolysis time is 2-3h. After grinding with a colloid mill, fresh pulp is obtained for use;
[0066] (4) Preparation of the medicinal fungus mixture: adding the live Akkermansia muciniphila obtained in step (2) to the tea vinegar mixture obtained in step (1), and fermenting under anaerobic conditions at 37° C. for 15 hours to obtain the medicinal fungus mixture;
[0067] The amount of live Akkermansia Muciniphila added was 4×10 9 pcs / 100mL tea vinegar mixture.
[0068] (5) blending: adding the fruit pulp obtained in step (3) to the medicinal fungus mixture obtained in step (4) for blending;
[0069] The amount of fruit pulp added is 10% of the mass of the medicinal fungus mixture.
[0070] (6) High-pressure homogenization sterilization: The medicinal fungus composition is subjected to homogenization sterilization treatment at 150 MPa and 45° C. to finally obtain a medicinal fungus composition for treating hyperlipidemia.
[0071] Comparative Example 1
[0072] (1) Preparation of tea vinegar mixture: Use ultrafine grinding method to grind high-quality green tea leaves. During the grinding, the speed of the ultrafine grinder is 350r / min, the ball-to-material ratio is 8, and the grinding time is 3.5h to obtain tea powder. Heat and concentrate the vinegar at a temperature of 80°C for 20h, and collect the distilled vinegar liquid and concentrated vinegar liquid. Add a certain amount of yeast extract to the concentrated vinegar liquid at a ratio of 1:200, mix well, let stand, and take the lower layer liquid to obtain the prepared vinegar paste. Then add 20% of the vinegar paste of the mass of the tea powder and mix to obtain a tea vinegar mixture.
[0073] (2) Pretreatment of fruit raw materials: Wash the fruit raw materials twice or take out the pulp, mix pitaya, kiwi fruit and cherry tomatoes in a mass ratio of 8:7:5 for pulping, add 0.1% of the total mass of the pulp cellulase and 0.2% of pectinase to the pulped pulp, the enzymolysis temperature is 45-55°C, and the enzymolysis time is 2-3h. After grinding with a colloid mill, fresh pulp is obtained for use;
[0074] (3) blending: adding the fruit pulp obtained in step (2) to the tea vinegar mixture obtained in step (1) for blending;
[0075] The amount of fruit pulp added is 10% of the mass of the tea vinegar mixture.
[0076] (6) High-pressure homogenization sterilization: The pharmaceutical composition is subjected to homogenization sterilization treatment at 150 MPa and 45°C.
[0077] Comparative Example 2
[0078] (1) Preparation of Akkermansia muciniphila: According to the HACCP quality system, the bacteria were cultured using food-grade culture medium and fermented under anaerobic conditions at 37° C. for 40 h to obtain live Akkermansia muciniphila for later use;
[0079] (2) Pretreatment of fruit raw materials: Wash the fruit raw materials twice or take out the pulp, mix pitaya, kiwi fruit and cherry tomatoes in a mass ratio of 8:7:5 for pulping, add 0.1% of the total mass of the pulp cellulase and 0.2% of pectinase to the pulped pulp, the enzymolysis temperature is 45-55°C, and the enzymolysis time is 2-3h. After grinding with a colloid mill, fresh pulp is obtained for use;
[0080] (3) blending: adding the fruit pulp obtained in step (2) to the live Akkermansia muciniphila obtained in step (1) to obtain a composite mixture;
[0081] 4×10 9 Add 100 mL of fruit puree to the inactivated Akkermansia muciniphila bacteria.
[0082] (4) High-pressure homogenization sterilization: The pharmaceutical composition is subjected to homogenization sterilization treatment at 150 MPa and 45°C.
[0083] Comparative Example 3
[0084] (1) Preparation of tea vinegar mixture: Use ultrafine grinding method to grind high-quality green tea leaves. During the grinding, the speed of the ultrafine grinder is 350r / min, the ball-to-material ratio is 8, and the grinding time is 3.5h to obtain tea powder. Heat and concentrate the vinegar at a temperature of 80°C for 20h, and collect the distilled vinegar liquid and concentrated vinegar liquid. Add a certain amount of yeast extract to the concentrated vinegar liquid at a ratio of 1:200, mix well, let stand, and take the lower layer liquid to obtain the prepared vinegar paste. Then add 20% of the vinegar paste of the mass of the tea powder and mix to obtain a tea vinegar mixture.
[0085] (2) Preparation of Akkermansia muciniphila: According to the HACCP quality system, the bacteria were cultured using food-grade culture medium and fermented under anaerobic conditions at 37° C. for 40 h to obtain live Akkermansia muciniphila for later use;
[0086] (3) Pretreatment of fruit raw materials: Wash the fruit raw materials twice or take out the pulp, mix pitaya, kiwi fruit and cherry tomatoes in a mass ratio of 8:7:5 for pulping, add 0.1% of the total mass of the pulp cellulase and 0.2% of pectinase to the pulped pulp, the enzymolysis temperature is 45-55°C, and the enzymolysis time is 2-3h. After grinding with a colloid mill, fresh pulp is obtained for use;
[0087] (4) Compounding: adding the live Akkermansia muciniphila obtained in step (2) to the tea vinegar mixture obtained in step (1) to obtain a compound mixture;
[0088] The amount of live Akkermansia muciniphila added was 4×10 9 pcs / 100mL tea vinegar mixture.
[0089] (5) blending: adding the fruit pulp obtained in step (3) to the composite mixture obtained in step (4) for blending;
[0090] The amount of fruit pulp added is 10% of the mass of the composite mixture.
[0091] (6) High-pressure homogenization sterilization: The composite composition is subjected to homogenization sterilization treatment at 150 MPa and 45°C.
[0092] Test Example Application Performance of the Medicinal Fungus Composition for Treating Hyperlipidemia
[0093] (1) Experimental animals:
[0094] 90 SD rats, 5-6 weeks old male.
[0095] Experimental reagents:
[0096] The composition of Example 1, Example 2, Example 3, Comparative Example 1, Comparative Example 2, Comparative Example 3, high-fat feed (78% formula basic feed, 1% cholesterol, 10% egg yolk powder and 10% lard, 1% bile salt), lovastatin tablets
[0097] Experimental methods:
[0098] The rats were randomly divided into 9 groups, 10 rats in each group, and divided into normal group, model group, drug administration group 1, drug administration group 2, drug administration group 3, drug administration group 4, drug administration group 5, drug administration group 6 and positive control group. The relationship between the groups and drug administration is shown in Table 1.
[0099] Table 1 Grouping and drug administration
[0100]
[0101] After one week of adaptive training, the rats were fed a normal diet and drank water; the model group was fed a high-fat diet for 20 days; the experimental group was fed a high-fat diet for 10 days, and the composition or lovastatin tablets were gavaged every day from the 10th to the 20th day, with a dose of 4 mL / kg and 0.15 g / kg, respectively. On the 21st day, the rats were killed by cervical dislocation. The serum of the rats was collected, and the TG, TC, and HDL-C in the serum of the rats were detected.
[0102] Table 2 Statistical results of relevant indicators in the serum of rats in each group
[0103]
[0104] Note: ### compared with the normal group, P < 0.001; ## compared with the normal group, P < 0.01; # compared with the normal group, P < 0.05; *** compared with the model group, P < 0.001; ** compared with the model group, P < 0.01; * compared with the model group, P < 0.05.
[0105] (2) The content index of the medicinal fungus composition obtained by the present invention is as follows:
[0106] Water content ≦40-50%, total polysaccharide content ≧4.36g / 100mL, total phenol content ≧5.00mg / mL, total flavonoids content ≧4.50mg / mL.
[0107] In summary, the product of the present invention can significantly reduce the content of TG and TC in the serum of rats with hyperlipidemia, reduce the serum blood lipid level, and increase the level of HDL-C in the serum. In general, the above results show that the product of the present invention has a significant effect in treating hyperlipidemia and can be used as a drug with a good effect in treating hyperlipidemia.
[0108] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.
Claims
1. A method for preparing a medicinal fungus composition for treating hyperlipidemia, characterized in that: The following steps are involved: S1, preparing vinegar paste by distillation and concentration method, mixing with tea powder to obtain tea vinegar mixture; S2. Akkermansia muciniphila Akkermansia muciniphila Anaerobic fermentation was performed at 35-38°C for 35-45 hours to obtain live bacteria; S3, adding the tea vinegar mixture to the live bacteria culture medium, and anaerobically fermenting at 35-38°C for 15-35h to obtain a medicinal bacteria mixture; S4, preparing the above-mentioned drug-bacteria mixture, and sterilizing it to obtain the drug-bacteria composition for treating hyperlipidemia; in, In step S1, the preparation method of the vinegar paste is as follows: heating the vinegar at 60°C to 80°C for 20 to 30 hours for distillation and concentration, collecting the concentrated vinegar liquid, adding the yeast extract thereto, mixing and separating the layers, and taking the lower layer to obtain the vinegar paste; In step S1, the tea powder is obtained by crushing green tea leaves by ultrafine grinding method; In step S3, the Akkermansia muciniphila Akkermansia muciniphila The amount of addition is 4×10 8 ~4×10 11 pcs / 100 mL tea vinegar mixture; In step S4, the preparation is as follows: adding fruit pulp to the medicinal fungus mixture; the fruit is a mixture of pitaya, cherry tomatoes and kiwi fruit, the pulp is a clarified pulp obtained by pulping and enzymolysis of fruit pulp, and the enzymolysis process is as follows: adding cellulase and pectinase to the pulped pulp for enzymolysis, the enzymolysis temperature is 45-55°C, and the enzymolysis time is 2-3 h.
2. The preparation method according to claim 1, characterized in that: The mass ratio of concentrated vinegar liquid to yeast extract is 100-300:1-1.
5.
3. The preparation method according to claim 1, characterized in that: In the tea-vinegar mixture, the vinegar paste accounts for 20-30% of the mass of the tea powder.
4. The medicinal fungus composition obtained by the preparation method according to any one of claims 1 to 3.
5. Use of the medicinal fungus composition according to claim 4 in the preparation of a medicament for preventing or treating hyperlipidemia.
